Aurolife Pharma
United States Updated 9 July 2026
Aurolife Pharma is a finished-dose manufacturer based in United States. It appears in 76 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its most recent recorded inspection, by US FDA, closed on 26 August 2022 as VAI.
2
registered plants
2 with an FDA FEI number
76
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 26 August 2022 VAI US FDA
- 7 December 2021 OAI US FDA
- 22 October 2019 VAI US FDA
- 14 June 2018 VAI US FDA
- 28 July 2016 NAI US FDA
- 12 January 2016 NAI US FDA
- 9 July 2015 NAI US FDA
- 15 October 2013 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Dayton, United States | 3005796917 |
| Durham, United States | 3014028588 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 76 | None |
Comparing suppliers?
Choose your molecules and target markets. Aurolife Pharma comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- 68 active litigation matters are on record.
- The most recent inspection outcome was VAI, on 26 August 2022.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability